Upsher-Smith to extend epilepsy drug trial

MAPLE GROVE, Minn. Drug maker Upsher-Smith Labs will add an extension study to its late-stage clinical trial of a drug for treating epilepsy, the company said Tuesday.

 

Upsher-Smith announced an additional study for patients who completed the phase-3 “Prevail” trial of the drug USL255 (topiramate extended-release). The drug is designed to provide a once-daily dosage for adults with the disease.

 

 

“The open-label extension study will provide additional long-term tolerability information regarding USL255 as adjunctive therapy in patients with refractory, partial-onset seizures who completed the phase-3 study and choose to participate in the extension study,” Upsher-Smith chief medical officer and VP medical and regulatory affairs Alan Rauch said.

 

Login or Register to post a comment.